• June 3-6, 2024
  • San Diego Convention Center, California

Sessions

Loading

miRecule Inc.

Monday, June 03, 2024
CP
Platform for Therapeutics
miRecule’s approach to drug design revolves around using a platform which integrates genomic sequencing, expression, and prognostic data from patients with high throughput screening of RNA to identify its drug candidates. The resulting Antibody-RNA Conjugates (ARCs), present a very promising opportunity that will significantly expand the targetome of antibody-based cancer therapy. RNA-based therapeutics hold out the promise of significantly lower cost-of-goods and the ability to rapidly modify and change (plug and play) therapeutics from an existing ARC scaffold. In 2022, miRecule entered into a strategic collaboration with Sanofi to develop a best-in-class nanobody-RNA conjugate to treat the second most common form of muscular dystrophy, Facioscapulohumeral Muscular Dystrophy (FSHD). Beyond this program, miRecule's own proprietary lead program, MC-30, targets the 6th most common form of cancer, head and neck cancer afflicting more than 30,000 patients annually.
miRecule Inc.
Company Website: https://mirecule.com/team/
Lead Product in Development: miRecule's own proprietary lead program, MC-30, targets the 6th most common form of cancer, head and neck cancer afflicting more than 30,000 patients annually, and addresses an estimated potential market opportunity of $3.2bil.
Number Of Unlicensed Products (For Which You Are Seeking Partners): multiple

Company HQ City

Gaithersburg

Company HQ State

MD

Company HQ Country

United States

CEO/Top Company Official

Anthony Saleh

Development Phase of Primary Product

Pre-Clinical
Back to Session List

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS